Tixagevimab-Cilgavimab: Utilization in the solid organ transplant population
Clin Transplant
.
2022 Jun;36(6):e14661.
doi: 10.1111/ctr.14661.
Epub 2022 May 16.
Authors
Suhail A Shaikh
1
,
Faiza Morado
2
,
Pnada Kawewat-Ho
1
,
Rachel Cartus
1
,
Roland Davoudi
1
,
Kevin Forrester
3
,
Krist Azizian
3
,
Emily Blodget
4
,
Thin Thin Maw
4
,
Neha Nanda
4
Affiliations
1
Keck Hospital of USC, USC Transplant Institute, University of Southern California, Los Angeles, California, USA.
2
Keck Hospital of USC, Department of Clinical Pharmacy, University of Southern California, Los Angeles, California, USA.
3
University of Southern California Health Sciences Center, Department of Clinical Pharmacy, Los Angeles, California, USA.
4
Keck Medical Center, Department of Medicine, University of Southern California, Los Angeles, California, USA.
PMID:
35396876
DOI:
10.1111/ctr.14661
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal
Humans
Organ Transplantation*
Transplant Recipients
Substances
Antibodies, Monoclonal
tixagevimab
cilgavimab